- Creso Pharma (CPH) has entered a trading halt to allow the company time to consider, plan and execute a capital raising
- The healthcare stock hasn’t stated how much it’s planning to raise just yet, with full details to be released by March 26
- That’s the last day the trading halt is in effect, with the capital raise announcement due out on or before Friday
- More recently, CPH has been focused on its planned acquisition of Halucenex Life Sciences, a Canadian psychedelics treatment company
- The purchase will position Creso as the first ASX-listed company with an established presence in the psychedelics market
- Shares in Creso Pharma last traded for 23 cents per share on March 23
Creso Pharma (CPH) has entered a trading halt to allow the company time to consider, plan and execute a capital raising.
The healthcare stock hasn’t stated how much it’s planning to raise just yet, with full details to be released by March 26 at the latest.
That’s the last day the trading halt will remain in effect, with the capital raise announcement due out on or before Friday.
Before today’s trading halt was announced, Creso had been focused on its planned acquisition of Halucenex Life Sciences.
Halucenex is a Canadian psychedelics treatment company that operates a medical treatment facility and controlled substances laboratory.
The business is in the process of acquiring a licence to possess and conduct research on psychedelics such as psilocybin, LSD and MDMA.
Creso’s Halucenex purchase will give the ASX-lister an established presence in the psychedelics market, making it the first among its peers.
Prior to the trading halt, shares in Creso Pharma were trading for 23 cents per share on Tuesday, March 23.